Medscape23h
Post-COVID Cough Linked to Neurological Dysfunction
Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.
Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total ...
pulmonologyadvisor7d
Chronic Cough Reduced Through Behavioral Cough Suppression Therapy
Behavioral cough suppression therapy may be effective in patients with refractory and unexplained chronic cough (RCC and UCC).
Exxel Pharma to Participate in a “New to Virtual Investor” Segment
AURORA, CO / ACCESS Newswire / January 31, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal ...
Sacramento Bee10d
Exxel Pharma’s Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...
Kansas City Star13d
Exxel Pharma to Participate in a “New to Virtual Investor” Segment
Exxel is initiating a first-in-human Phase 1/1b clinical study of EX937 for refractory chronic cough, a significant unmet medical need with no FDA-approved treatments. In preclinical studies ...
Eagle-Tribune10d
Exxel Pharma's Innovative Small Molecule, EX937, Rapidly Advancing Toward First-In-Human Study for the Treatment of Refractory Chronic Cough
Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...